Cardiac patients had reason to celebrate the Food & Drug Administration's Oct. 7 approval of Heartport's new heart surgery technique. So did Wall Street. Heartport's technology lets doctors do bypasses and valve replacements through incisions cut between the ribs, rather than opening up the chest, reducing complications and recovery time. Shares surged 23%, on huge volume. They had spurted 13% the day before, too, indicating that news of the FDA's approval may have leaked early.
EDITED BY KEITH H. HAMMONDS
Updated June 14, 1997 by bwwebmaster
Copyright 1996, Bloomberg L.P.